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Abstract
Background: Patients infected with the novel coronavirus SARS-CoV-2 are frequently hospi-
talized with community-acquired pneumonia (CAP). The objective of this study was to define 
the clinical characteristics and outcomes of hospitalized patients with SARS-CoV-2 CAP in the 
city of Louisville, KY.
Methods: This was a retrospective observational study of 700 patients with SARS-CoV-2 in-
fection hospitalized to eight of the adult hospitals in the city of Louisville. Patients with 1) a 
positive RT-PCR for SARS-CoV-2, 2) fever, cough, or shortness of breath, and 3) an infiltrate at 
chest imaging were defined as having SARS-CoV-2 CAP. Demographic characteristics of the 
study population were compared with census data from the city of Louisville. For each patient 
more than 500 variables were abstracted from electronic medical records and recorded using 
Research Electronic Data Capture software. Data was analyzed by descriptive and inferential 
statistics using R version 3.4.0.
Results: SARS-CoV-2 CAP was identified in 632 (90%) patients hospitalized with COVID-19. 
The median age of the patients was 63 years, 53% were females, 31% were black and 12% 
Hispanic. The most frequent comorbidities were hypertension (56%), obesity (50%), and dia-
betes (33%). Mortality was 17% for the total population and 34% for the 249 patients admitted 
to ICU. For each category of race, ethnicity and comorbidities, the proportion of hospitalized 
patients with SARS-CoV-2 CAP was significantly different when compared to the Louisville 
population (p < 0.001).
Conclusion: Patients of black race, Hispanic ethnicity, and patients with history of hyperten-
sion, obesity or diabetes are overrepresented among hospitalized patients with SARS-CoV-2 
CAP when compared to the Louisville population. Hospitalized patients with SARS-CoV-2 CAP 
are likely to require ICU care, with death occurring in approximately one of six hospitalizations.
Introduction
Coronavirus disease 2019 (COVID-19) is a multisystem disease produced by the novel 
coronavirus SARS-CoV-2. COVID-19 manifests usually as an influenza-like syndrome 
due to multiplication of SARS-CoV-2, primarily in the epithelial cells of the upper re-
spiratory tract. More severe disease occurs when the virus invades and multiplies in the 
lower respiratory tract particularly in alveolar epithelial type II cells. [1] At this stage 
the patient will present with a clinical syndrome of community-acquired pneumonia 
(CAP). SARS-CoV-2 CAP is a common clinical presentation in hospitalized patients with 
COVID-19. If the infection advances, viral replication accelerates, and the epithelial-en-
dothelial barrier integrity is compromised. At this next stage the patient may develop 
acute respiratory distress syndrome (ARDS) due to pulmonary edema filling the alveolar 
spaces with hyaline membrane formation. [1] 
A significant amount of literature has been published describing the characteristics and 
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outcomes of patients hospitalized with COVID-19, but clinical characteristics of patients with SARS-CoV-2 CAP, as well 
as their clinical outcomes, has been described in a limited number of studies. Before the development of the COVID-19 
pandemic, we completed a population-based study of all hospitalized patients with CAP in the city of Louisville, KY. 
We prospectively enrolled all consecutive patients with CAP hospitalized to any of the adult hospitals in the city of 
Louisville during a period of 2 years. [2] Taking advantage of this well-established city-wide clinical research network, 
we evaluated the first 700 hospitalized patients with a diagnosis of COVID-19 with the objective to define the clinical 
characteristics and outcomes of hospitalized patients with SARS-CoV-2 CAP in the city of Louisville.
Methods
Study Design, Subjects, and Setting
This was a retrospective observational study of the first 700 patients with a diagnosis of SARS-CoV-2 hospitalized to 
any of the eight adult hospitals in the city of Louisville, KY. The study started on March 5 2020, when the first hos-
pitalized patient with COVID-19 was identified in Louisville and ended on July 1 2020. Patients’ follow-up ceased at 
hospital discharge.
Data Collection
Data were abstracted from hospital electronic medical records. Collected data included patient age, sex, race, ethnicity, 
body mass index, residence, medical and social history, physical examination findings, laboratory findings, chest radio-
graphs and chest CT findings, medications, intensive care unit (ICU) admission, and need for mechanical ventilation. 
Race was categorized as black, white, and other. Ethnic group was categorized as Hispanic or non-Hispanic. Race and 
ethnicity were treated independently for analysis.
Study Definitions
SARS-CoV-2 Infection: A patient hospitalized with a positive SARS-CoV-2 reverse transcriptase polymerase chain reac-
tion (RT-PCR) from a nasopharyngeal swab or other respiratory sample. 
SARS-CoV-2 CAP: A patient hospitalized with SARS-CoV-2 infection with fever, cough, or shortness of breath, and 
with evidence of pulmonary infiltrates at chest radiograph or chest computer tomography scan (CT-scan).
SARS-CoV-2 CAP with ARDS: A patient with SARS-CoV-2 CAP with evidence of acute respiratory distress syndrome 
(ARDS) define as bilateral opacities on a chest radiograph or computed tomographic (CT) scan not fully explained by 
cardiac failure or fluid overload with PaO2/FiO2 ≤300 mmHg, on ventilator settings that include positive end-expira-
tory pressure (PEEP) ≥5 cm H2O. [3]
 
Clinical Presentation 
The National Institutes of Health (NIH) guidelines for COVID-19 classified adults with SARS-CoV-2 infection in sever-
al severity of illness categories. [4] Using the NIH model, we classified the clinical presentation of hospitalized patients 
with COVID-19 in 9 stages. The following definitions were used:
Stage 1: SARS-CoV-2 Asymptomatic Infection. A patient with positive SARS-CoV-2 RT-PCR and no COVID-19 related 
symptoms.
Stage 2: SARS-CoV-2 Mild Infection. A patient with positive SARS-CoV-2 RT-PCR and COVID-19 related symptoms but 
without evidence of pulmonary infiltrates at chest imaging (e.g. no evidence of CAP).
 
Stage 3: SARS-CoV-2 CAP with no supplemental oxygen. A patient with SARS-CoV-2 CAP not receiving supplemental 
oxygen.
Stage 4: SARS-CoV-2 CAP and low-flow supplemental oxygen.  A patient with SARS-CoV-2 CAP receiving supplemental 
oxygen delivered by a low-flow system (e.g. nasal cannula). 
Stage 5: SARS-CoV-2 CAP and high-flow supplemental oxygen or non-invasive ventilation. A patient with SARS-CoV-2 
CAP receiving supplemental oxygen delivered by a high-flow system (e.g. high-flow nasal cannula) or non-invasive 
ventilation. 
Stage 6: SARS-CoV-2 CAP and mechanical ventilation. A patient with SARS-CoV-2 CAP intubated receiving invasive 
mechanical ventilation.
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Stage 7: SARS-CoV-2 CAP and Mild ARDS. A patient with SARS-CoV-2 CAP on mechanical ventilation and develop-
ment of ARDS with a PaO2/FiO2 >200 mmHg, but ≤300 mmHg.
Stage 8: SARS-CoV-2 CAP and Moderate ARDS. A patient with SARS-CoV-2 CAP on mechanical ventilation and devel-
opment of ARDS with a PaO2/FiO2 >100 mmHg, but ≤200 mmHg.
 
Stage 9: SARS-CoV-2 CAP and Severe ARDS. A patient with SARS-CoV-2 CAP on mechanical ventilation and develop-
ment of ARDS with a PaO2/FiO2 is ≤100 mmHg. 
Severity of Disease & Mortality Prediction
Severity of SARS-CoV-2 CAP at time of hospitalization and mortality prediction was evaluated using two well estab-
lished CAP scores, the pneumonia severity index (PSI) score and the CURB-65 score. [5,6].
SARS-CoV-2 RNA Levels
Relative SARS-CoV-2 RNA levels at time of hospitalization were estimated using the number of cycles in the RT-PCR 
assay needed to amplify viral RNA to reach a detectable level (cycle threshold). Levels of relative SARS-CoV-2 RNA 
were classified as low, intermediate and high.
Geospatial Epidemiology
The geomasked location of the home address of each patient with SARS-CoV-2 CAP who was enrolled in the study was 
obtained through the US Census Bureau website. [7] A kernel density heatmap was created using each patient’s address 
at the time of SARS-CoV-2 CAP hospitalization. Areas of elevated relative risk of contracting SARS-CoV-2 CAP based 
on underlying population density were identified using Kuldorff ’s spatial scan statistic.
Cardiac and Cardiovascular Events
The following cardiac or cardiovascular events that were present at the time of admission or developed during hospi-
talization were collected: development of heart failure, cardiac arrest, cardiogenic shock, acute myocardial infarction, 
pulmonary edema, new arrhythmia, acute worsening of a chronic arrhythmia, cerebrovascular accident, pulmonary 
embolism, myocarditis, and deep vein thrombosis.
Co-Infections
A patient with an isolated micro-organism from blood, respiratory, or urine samples was defined as having a co-infec-
tion. Community-acquired co-infections were defined as identification of micro-organisms during the first 3 days of 
hospital admission. Hospital-acquired co-infections were defined as micro-organisms identified more than 3 days after 
hospital admission.
Clinical Outcomes
Patients who were discharged alive were considered as clinical successes and patients who died during hospitalization 
were considered as clinical failures. Binary outcomes evaluated included need for invasive mechanical ventilation, ad-
mission to ICU, septic shock, ARDS, and death. Time-to-event outcomes evaluated included time to hospital discharge, 
time to initiation of mechanical ventilation, time to ICU admission, time to septic shock, time to ARDS, and time to 
death. 
Statistical Analysis
Continuous patient characteristics were summarized as medians and interquartile ranges and categorical patient 
characteristics were summarized as frequencies and percentages. Comparisons to Louisville demographics were per-
formed using one-sample t-tests of proportions, with null values equal to the Louisville proportion, taken from the 2017 
Behavioral Risk Factor Surveillance System (BRFSS) Smart Data database and the 2019 American Community Survey 
5-year estimates. [8,9] Analyses were performed with R version 3.4.0. P values were 2 sided, with statistical significance 
set at p < 0.05.
Study Coordinating Center
The Center of Excellence for Research in Infectious Diseases (CERID) located at the University of Louisville Division 
of Infectious Diseases, directed all operations of the study (CERIDlouisville.org).  Members of CERID developed the 
study data collection form and the study database, collected data from hospital electronic medical records and record-
ed data into the study database. Data were collected and managed using REDCap electronic data capture tools hosted 
at the University of Louisville. REDCap (Research Electronic Data Capture) is a secure, web-based software platform 
designed to support data capture for research studies, providing an intuitive interface for validated data capture. [10] 
The CERID data quality team performed quality control of collected data. After all data queries were resolved, the 
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study database was locked for data analysis. 
Human Subjects Protection
The study was approved by the Institutional Review Board (IRB) at the University of Louisville Human Subjects Re-
search Protection Program Office (IRB number 20.0257) and by the research offices at each participating hospital. The 
study was exempt from informed consent. 
Results
Study Population and Clinical Presentation
From a total of 700 patients hospitalized with COVID-19, a total of 632 patients (90%) were hospitalized with SARS-
CoV-2 CAP. A bar chart describing the patients’ clinical presentation at time of hospitalization is depicted in Figure 1. 
The most common clinical presentation was SARS-CoV-2 CAP in patients not receiving supplemental oxygen (stage 3). 
The primary clinical diagnoses at time of hospitalization for 68 patients in stages 1 and 2 (patients without SARS-CoV-2 
Figure 1. Study bar chart indicating the number of COVID-19 hospitalized 
patients in each one of the nine stages of clinical presentation.
CAP) included labor, trauma, and urinary tract infections. Demographics and comorbidities for hospitalized patients 
with SARS-CoV-2 CAP are depicted in Table 1. 
Comparisons of SARS-CoV-2 CAP patients’ demographics to the Louisville population are shown in Figure 2. Compar-
isons of SARS-CoV-2 CAP patients’ comorbidities to the Louisville population are shown in Figure 3. All comparisons 
between patient demographics and comorbidities to the Louisville population were statistically significant (p<0.001).
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Variable Value
Total N 632
Age (median [IQR]) 63 [48, 74]










Hypertension (%) 352 (56)
Obesity (%) 315 (50)
Diabetes (%) 214 (33)
Renal Disease (%) 119 (19)
Heart failure (%) 99 (16)
Coronary artery disease (%) 95 (15)
COPD (%) 96 (15)
Cerebrovascular disease (%) 86 (14)
Asthma (%) 67 (11)
Obstructive sleep apnea (%) 60 (9)
Neoplastic disease (active or within the last 
year) (%) 45 (7)
Other immunocompromising condition or 
therapies (%) 29 (5)
Liver disease (non-cirrhotic) (%) 21 (3)
Cirrhosis (%) 8 (1)
Table 1. Patient Demographics and Medical History.
Figure 2. Comparison of patient demographics to those of the city of Louisville. 
All data are reported as percentage of the population with the demographic.
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Figure 3. Comparison of patient comorbidities to those of the city of Louisville. 
All data are reported as percentage of the population with the comorbidity.
The age distribution showing the number of adults hospitalized with SARS-CoV-2 CAP is depicted in Figure 4. A com-
parison of the percentage distribution of age groups between adults hospitalized with SARS-CoV-2 CAP and the adult 
Louisville population is shown in Figure 5. 
Figure 4. Histogram depicting the number of patients with SARS-CoV-2 CAP 
per age group.
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Figure 5. Comparison of percentage distribution of SARS-CoV-2 CAP patient 
age to the Louisville population (left) patients hospitalized with SARS-CoV-2 
CAP, (right) the adult population of Louisville.
Table 2. Signs and Symptoms for patients hospitalized with 
SARS-CoV-2 CAP.
Signs and symptoms in patients with SARS-CoV-2 CAP are depicted in Table 2. Median time from symptoms onset to 
hospitalization was 4 days. 
Vital signs and laboratory values for patients hospitalized with SARS-CoV-2 CAP at admission are depicted in Table 3. 
The characteristic chest CT-scans imaging of diffuse, peripheral ground-glass opacities were present in 324 of 439 
(74%) patients with chest CT performed.
Medications used in adults hospitalized with SARS-CoV-2 CAP during hospitalization are depicted in Table 4.
Variable Value
Total N 632
Fever or subjective fever (%) 436 (69)
Cough (%) 425 (67)
Dyspnea (shortness of breath) (%) 407 (64)
Fatigue (%) 218 (34)
Muscle Ache (myalgia) (%) 160 (25)
Nausea (%) 139 (22)
Diarrhea (%) 114 (18)
Sputum Production (%) 95 (15)
Vomiting (%) 79 (12)
Chest pain/tightness (%) 78 (12)
Confusion (%) 71 (11)
Headache (%) 71 (11)
Sore Throat (%) 52 (8)
Nasal Congestion (%) 52 (8)
Dizziness (%) 42 (7)
Rhinorrhea (runny nose) (%) 21 (3)
Anosmia (%) 15 (2)
Agusia (%) 15 (2)
Hemoptysis (blood in sputum) (%) 7 (1)
Constipation (%) 4 (1)
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Variable Median n
Heart Rate (beats/min)  96.5 [82.0, 111.0] 632
Respiratory Rate (breaths/min)  22.0 [18.0, 27.0] 632
Systolic Blood Pressure (mmHg) 121.0 [106.0, 140.2] 632
Diastolic Blood Pressure (mmHg)  67.5 [57.0, 80.0] 632
Temperature (degrees C)  37.7 [37.0, 38.7] 632
SpO2 / FiO2 428.6 [290.6, 452.4] 631
PaO2 / FiO2 187.2 [99.2, 297.7] 238
WBC x 1000 per uL   6.3 [4.6, 8.8] 627
Neutrophils x 1000 per uL   4.6 [3.0, 7.4] 610
Lymphocytes x 1000 per uL   1.0 [0.7, 1.4] 615
Neutrophil / Lymphocyte   4.5 [2.7, 7.8] 609
Hematocrit (%)  38.8 [35.2, 42.4] 627
Glucose (mg/dL) 123.0 [104.0, 166.0] 629
Blood urea nitrogen (mg/dL)  17.0 [11.0, 28.2] 626
Creatinine (mg/dL)   1.0 [0.7, 1.4] 627
Ferritin (ng/dL) 398.0 [176.0, 891.0] 435
Procalcitonin (ug/L)   0.1 [0.1, 0.4] 504
Lactate (mmol/L)   1.3 [1.1, 1.8] 465
D-Dimer (ng/mL) 736.0 [388.5, 1517.0] 447
IL-6 (pg/mL)  58.2 [29.6, 131.3] 198
C-reactive protein (mg/L)  79.3 [38.0, 170.1] 436
Table 3. Vital signs and Laboratory Values. The third column depicts the 
number of patients for whom data was available.
Variable Value
Total n 632
Azithromycin (%) 398 (63)
Low molecular weight Heparin (%) 394 (62)
Hydroxychloroquine (%) 239 (38)
Steroid (%) 145 (23)
Heparin (%) 114 (19)
Convalescent plasma (%) 50 (8)
Remdesivir (%) 31 (5)
Table 4. Medications for treatment of SARS-CoV-2 CAP.
Severity of Disease & Associated Mortality
The severity of CAP at time of hospitalization according to CURB-65 and PSI scores with associated mortality per class 
or score are depicted in Figure 6. 
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Figure 6. The distribution of patients hospitalized with SARS-CoV-2 CAP in 
PSI risk classes (top-left) and the distribution of patients hospitalized with 
SARS-CoV-2 CAP in CURB-65 scores (top-right) are shown in the top of the 
figure. The associated percentage of in-hospital mortality by PSI risk class 
(bottom-left) and by CURB-65 score (bottom-right) are shown below. 
SARS-CoV-2 RNA Levels
Cycle threshold (CT) values were available for a total 405 SARS-CoV-2 CAP patients. For these patients, the lowest CT 
value from the N1, N2, and N3 genes was used to represent the relative viral RNA levels, as a lower CT value indicates a 
high viral load. CT values are depicted in Figure 7.
Figure 7. Distribution of the lowest CT value from the N1, N2, and N3 gene. 
Lower CT values are analogous to higher viral loads. Level of viral load was 
classified into high, intermediate, and low.
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Geospatial Epidemiology
The kernel density heatmap created using each patient’s home address at the time of hospitalization due to SARS-
CoV-2 CAP is depicted in Figure 8.
Figure 8. Kernel density heatmap of residential addresses of patients 
hospitalized with SARS-CoV-2 CAP. Four distinct areas of elevated risk are 
identified in the dashed circles.
Cardiac and Cardiovascular Events
A total of 120 patients (19%) developed cardiac or cardiovascular events. The list of cardiac and cardiovascular events 
is depicted on Table 5.
Variable Value
Total n 632
New arrhythmia (%) 52 (8)
Heart failure (%) 25 (4)
Cardiac arrest (%) 20 (3)
Acute worsening of chronic arrhythmia (%) 20 (3)
Cardiogenic shock (%) 15 (2)
Acute myocardial infarction (%) 13 (2)
Pulmonary edema (%) 13 (2)
Cerebrovascular accident (%) 7 (1)
Pulmonary embolism (%) 6 (1)
Deep vein thrombosis (%) 6 (1)
Myocarditis (%) 2 (<1)
Table 5. Cardiac and cardiovascular events in patients 
hospitalized due to SARS-CoV-2 CAP.
Co-Infections
A total of 67 SARS-CoV-2 CAP patients had co-infections. The list of patients with community-acquired (n=25) and 
hospital-acquired (n=42) co-infections is depicted on Table 6. For each type of co-infection, the culture sites were 
characterized.
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Community-Acquired Coinfections
Variable Number of Patients Culture Site
Escherichia coli 7 Blood culture (n=2), Urine culture (n=5)
Klebsiella pneumoniae 3 Sputum (n=1), Urine culture (n=2)
Haemophilus influenzae 2 Sputum (n=2)
Streptococcus pneumoniae 2 Sputum (n=2)
Acinetobacter spp. 1 Sputum (n=1)
Enterobacter spp. 1 Urine culture (n=1)
Influenza B 1 BAL (n=1)
Moraxella catarrhalis 1 Sputum (n=1)
Parainfluenza Virus 1 BAL (n=1)
Pseudomonas aeruginosa 1 Urine culture (n=1)
Respiratory Syncytial Virus 1 BAL (n=1)
MSSA 1 Sputum (n=1)
Streptococcus bovis 1 Blood culture (n=1)
Streptococcus pyogenes 1 Blood culture (n=1)
Candida spp. 1 Blood culture (n=1)
Hospital-Acquired Coinfections
Organism Number of Patients Culture Site
MRSA 9 Blood culture (n=1), Sputum (n=7), Urine culture (n=1)
Enterobacter spp. 5 Blood culture (n=2), Sputum (n=3)
Klebsiella pneumoniae 5 Sputum (n=3), BAL (n=1), Urine culture (n=1)
Pseudomonas aeruginosa 5 Blood culture (n=1), Sputum (n=2), BAL (n=1), Urine culture (n=1)
Escherichia coli 4 Sputum (n=1), Urine culture (n=3)
Stenotrophomonas spp. 4 Sputum (n=3), BAL (n=1)
Citrobacter spp. 2 Sputum (n=1), BAL (n=1)
Serratia spp. 2 Sputum (n=1), Urine culture (n=1)
Candida spp. 2 Blood culture (n=1), Urine culture (n=1)
Aspergillus spp. 2 Sputum (n=2)
Corona Virus OC43 1 NP swab (n=1)
MSSA 1 Sputum (n=1)
Table 6. Number of patients with coinfections, micro-organisms, and culture sites in adults hospitalized with 
SARS-CoV-2 CAP.
Clinical Outcomes
From the total population of 632 patients hospitalized with SARS-CoV-2 CAP, clinical success (discharged alive) was 
documented in 527 (83%) patients and clinical failure (died during hospitalization) in 105 (17%) patients. The median 
length of hospital stay was 7 days. Time to hospital discharge and time to in-hospital death is depicted in Figure 9A and 
9B. A total of 249 patients were admitted to the ICU, with 124 admitted on the first day. A total of 159 patients required 
mechanical ventilation. Mortality among patients admitted to the ICU was 34%. Time to ICU admission and time to 
mechanical ventilation are depicted in Figure 9C and 9D. Over the course of hospitalization, a total of 85 patients with 
SARS-CoV-2 CAP developed septic shock and 98 patients developed ARDS. Time to septic shock and time to ARDS 
are depicted in Figure 9E and 9F. Mortality was much higher in comorbid patients, ranging from 16 to 36%. Figure 10 
depicts crude mortality by demographics and comorbidities.
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Figure 9. Time to event outcomes, in days. A) Time to discharge from 
admission, B) time to mortality from admission, C) time to ICU admission, D) 
time to initiation of IMV, E) time to septic shock, F) time to ARDS.
Figure 10. Mortality by demographics and comorbid conditions. The 
percentage mortality in each group is displayed.
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Discussion
Our study indicates that SARS-CoV-2 CAP is present in 90% of all patients hospitalized with COVID-19. We previously 
described the clinical characteristics of hospitalized patients in the city of Louisville with CAP due to the four endemic 
serotypes of coronaviruses. [11] The most frequent serotype causing CAP was CoV-OC43, followed by CoV-229E, CoV-
HKU1, and CoV-NL63. At this time, SARS-CoV-2 has emerged as the predominant coronavirus causing CAP. 
Hospitalized COVID-19 patients without CAP constitute a heterogenous population. The most common admission di-
agnoses in patients without CAP included labor & delivery and trauma. In the majority of these patients COVID-19 was 
present as an asymptomatic infection. 
Among the patients hospitalized with SARS-CoV-2 in the city of Louisville, adults of black race or Hispanic ethnicity 
are overrepresented in relation to the census population of the city. Our study supports data from other areas of the 
Unites States indicating a higher percentage of black patients hospitalized with COVID-19. [12] 
Hypertension was the most frequent comorbidity in hospitalized patients with SARS-CoV-2 CAP in Louisville. Patients 
with hypertension, as well as patients with obesity, diabetes, renal disease, coronary artery disease, COPD, and cere-
brovascular disease were overrepresented in the population hospitalized with SARS-CoV- 2 CAP when compared to 
the general Louisville population. Hypertension was also reported as the most common comorbidity in hospitalized 
patients in a large CDC multicenter study. [13] 
A clinical syndrome of CAP was the predominant clinical presentation of COVID-19 in hospitalized patients. The most 
common signs and symptoms in our population were fever, cough, and shortness of breath. These are the most frequent 
signs and symptoms for hospitalized patients with COVID-19 in the US. [13] Some of our patients presented with a 
flu-like clinical syndrome characterized by fever, sore throat, fatigue and muscle aches. During the next winter season, 
the flu-like illnesses produced by SARS-CoV-2 will need to be added to the differential diagnosis of flu-like illness 
produced by other winter respiratory viruses. Surveillance data on circulating respiratory viruses in the community 
will be important to facilitate the clinical management of patients with flu-like illness this winter. SARS-CoV-2 started 
to circulate in the Louisville community at the end of the 2019-2020 winter season. Coincidental to the emergence of 
SARS-CoV-2 in Louisville, we documented a significant decrease in the circulation of other serotypes of coronavirus, 
as well as a decrease in respiratory syncytial virus, rhinovirus, and influenza. [14] The decrease in common respiratory 
viruses at the end of last winter was most likely related to the different steps implemented in the city related to social 
distancing, primarily, the closure of non-essential businesses. 
  
Severity of CAP at time of hospitalization is usually evaluated using the PSI score or the CURB-65 score. When we ap-
plied these scores to our population of hospitalized patients with SARS-CoV-2 CAP, the CURB-65 score better discrim-
inated risk of death during hospitalization, from 3% risk for death in patients with a score of 0, to 70% risk for death for 
patients with a score of 5. Physicians may use the CURB-65 to supplement clinical judgment when evaluating severity 
and risk of death in patients with SARS-CoV-2 CAP. One weakness of our study is the lack of data regarding ambulatory 
patients with COVID-19 in the city of Louisville, therefore we cannot evaluate the role of severity scores in deciding 
ambulatory care.
On the first day of hospitalization, need for ICU care was documented in 20% of our SARS-CoV-2 CAP population. A 
high proportion of patients hospitalized with COVID-19 requiring initial high level of care was also documented in a 
large cohort study in the United Kingdom. [15] Admission to the ICU during the first day of hospitalization may indi-
cate a rapid progression of SARS-CoV-2 infection in some patients or may indicate that some patients may not look for 
early medical attention. The initial treatment strategies from the time of study were not evidence-based, as there was a 
lack of studies from the corresponding study period. It is also important to note that several patients hospitalized with 
SARS-CoV-2 CAP were treated with hydroxychloroquine. This medication is not currently recommended for hospital-
ized patients, but a series of patients hospitalized at the beginning of the pandemic were treated with hydroxychloro-
quine even though the evidence for its efficacy was lacking.
Using the initial cycle threshold (Ct) levels, we estimated the SARS-CoV-2 viral load at the time of hospitalization in 
405 patients with SARS-CoV-2 CAP. Ct values are inversely proportional to the amount of the target nucleic acid in the 
sample. [16] We identified some patients with high Ct values, indicating very low viral loads at time of hospitalization. 
It has been suggested that the concentration of viral RNA in throat swabs may be already on the decline for some pa-
tients at the time of initial presentation. [17]
The heatmap of patients hospitalized with SARS-CoV-2 in the city of Louisville identifies areas of high relative risk that 
are very similar to areas that we previously identified as high risk for hospitalization due to CAP. [2] The clustering of 
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hospitalized patients with CAP as well as SARS-CoV-2 CAP in the western section of the city is associated with census 
tracts where the average population has low annual income and is of predominantly black race.
Cardiovascular events at time of hospitalization or during hospitalization were documented in 19% of hospitalized pa-
tients with SARS-CoV-2 CAP. New arrhythmias were the most frequent cardiovascular event, taking place in 8% of the 
patients hospitalized with SARS-CoV-2 CAP. Cardiovascular complications may be due to increased cardiac demand 
produced by the infection, destabilization of vascular plaques due to systemic inflammation, hypercoagulability due to 
endothelial damage, or direct heart damage due to SARS-CoV-2. [18]
A systematic review identified co-infections in 7% of hospitalized COVID-19 patients. [19] We identified co-infections 
in 8% of our SARS-CoV-2 CAP cohort; 25 were community-acquired and 42 were hospital-acquired. Viral respiratory 
infections such as influenza can predispose patients to co-infections of the respiratory tract. SARS-CoV-2 seems to pre-
dispose patients to infections in the respiratory tract but also outside of the respiratory tract. As an example, our group 
reported a case of a hospitalized patient with SARS-CoV-2 CAP and concomitant Escherichia coli bacteremia due to a 
prostatic abscess. [20] 
Proper assessment of clinical outcomes is a crucial component of current research efforts in the field of COVID-19. 
Studies of therapeutic interventions that evaluate clinical outcomes for all hospitalized patients with COVID-19 may be 
biased by the heterogenous population that is admitted to the hospital with the general diagnosis of COVID-19. In our 
study of 632 hospitalized patients with SARS-CoV-2 and a clinical diagnosis of CAP, we evaluated five binary outcomes 
and six time-to-event outcomes. The mean length of stay was 7 days, with an in-hospital mortality of 17%. For patients 
in the ICU mortality was 34%. The ICU mortality in our cohort is higher than the mortality of 26% reported in a study 
of patients hospitalized to ICUs at 72 hospitals in Italy. [21]
In conclusion, SARS-CoV-2 CAP is the primary reason for hospitalization of patients with COVID-19. Patients with 
SARS-CoV-2 CAP account for 90% of COVID-19 hospitalizations with an in-hospital mortality of 17%. Community 
members who are elderly, of black race, Hispanic ethnicity, and having medical comorbidities are at high risk for hospi-
talization. The primary medical comorbidities in our population were hypertension, obesity, diabetes, renal disease and 
cerebrovascular disease. Future research in hospitalized patients with COVID-19 should concentrate primarily on the 
development of new management and treatment strategies for patients with SARS-CoV-2 CAP.  
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